Shouq Alkhudhayri, Rania Sajini, Bashayer Alharbi, Jumana Qabbani, Yosra Al-Hindi, Arwa Fairaq, Amal Yousef
Objectives: Worldwide, diabetic neuropathy (DN) is a major complication of diabetes mellitus. The direct renin inhibitor aliskiren is recognized as a treatment for cardiovascular disease in diabetic patients, but little is known about its potential benefits in cases of diabetic neuropathy. Accordingly, we investigated the effects of aliskiren (ALIS) and gliclazide (GLZ) and their combination therapy on peripheral neuropathy in streptozotocin-induced diabetic rats. Methods: In total, 112 adult Sprague-Dawley rats were used for this study...
April 2021: Endocrinology, Diabetes & Metabolism